Report cover image

TIM-3 Inhibitor - Pipeline Insight, 2025

Publisher DelveInsight
Published Apr 01, 2025
Length 60 Pages
SKU # DEL19993612

Description

DelveInsight’s, “TIM-3 Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TIM-3 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
TIM-3 Inhibitor Understanding

TIM-3 Inhibitor: Overview

T-cell immunoglobulin and mucin domain 3 (Tim-3) is an immunoglobulin and mucin domain-containing cell surface molecule. The protein is characterized by a common structural organization consisting of an amino-terminal immunoglobulin variable domain (V domain) with five noncanonical cysteines, a mucin stalk, a transmembrane domain and a cytoplasmic tail. TIM-3 is known to interact with four ligands, galectin-9, phosphatidylserie (PtdSer), CEACAM-1and HMGB1 (high mobility group box-1). Tim-3 is a checkpoint receptor expressed by a wide variety of immune cells as well as leukemic stem cells. Various preclinical data support the therapeutic modulation of TIM3 in multiple disease contexts including autoimmunity, infection, and cancer. The blocking of Tim-3 and PD-1 together can result in reduced tumor progression in preclinical models and can improve antitumor T-cell responses in cancer patients.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence TIM-3 Inhibitor R&D. The therapies under development are focused on novel approaches for TIM-3 Inhibitor.
TIM-3 Inhibitor Emerging Drugs Chapters

This segment of the TIM-3 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TIM-3 Inhibitor Emerging Drugs
  • Cobolimab: GlaxoSmithKline
Cobolimab is a novel IgG4 anti-TIM-3 monoclonal antibody. It is under clinical investigation in clinical trial in combination with Dostarlimab and Docetaxel in Advanced Non-small cell lung cancer (NSCLC). By binding to and blocking TIM-3, Cobolimab allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth.
  • BMS-986258: Bristol-Myers Squibb
BMS-986258 (anti-TIM-3) is a fully-human monoclonal antibody targeting TIM-3 (T cell immunoglobulin and mucin domain-3). It is the first clinical candidate from the discovery collaboration between Five Prime Therapeutics and BMS that includes targets in three immune checkpoint pathways.

Further product details are provided in the report……..

TIM-3 Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different TIM-3 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on TIM-3 Inhibitor
There are approx. 15+ key companies which are developing the TIM-3 Inhibitor. The companies which have their TIM-3 Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Novarits Oncology.
  • Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
TIM-3 Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TIM-3 Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIM-3 Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIM-3 Inhibitor drugs.

TIM-3 Inhibitor Report Insights
  • TIM-3 Inhibitor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
TIM-3 Inhibitor Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing TIM-3 Inhibitor drugs?
  • How many TIM-3 Inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for TIM-3 Inhibitor?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIM-3 Inhibitor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for TIM-3 Inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Novarits
  • GlaxoSmithKline
  • Roche
  • Incyte Corporation
  • Bristol-Myers Squibb
  • Novartis
  • Interprotein
  • TrueBinding
  • Celgene
  • Sutro Biopharma
  • Neologics Bioscience
  • Symphogen
Key Products
  • Sabatolimab
  • Cobolimab
  • RG-7769
  • INCAGN 02390
  • BMS 986258
  • MAS-825
  • Research program: anticancer peptide therapeutics
  • Anti-T-cell immunoglobulin and mucin domain-3 monoclonal antibody
  • Research program: antibody based therapeutics
  • NB 002
  • Sym-023

Table of Contents

60 Pages
Introduction
Executive Summary
TIM-3 Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TIM-3 Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
TIM-3 Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
TIM-3 Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Sabatolimab: Novarits Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BMS 986258: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Sym 023: Symphogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NB 002: Neologics Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TIM-3 Inhibitor Key Companies
TIM-3 Inhibitor Key Products
TIM-3 Inhibitor- Unmet Needs
TIM-3 Inhibitor- Market Drivers and Barriers
TIM-3 Inhibitor- Future Perspectives and Conclusion
TIM-3 Inhibitor Analyst Views
TIM-3 Inhibitor Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us